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ABSTRACT (240 words, max 250 words) 
Renal function is the most commonly applied patient-specific, quantitative variable used to 
determine drug doses. Measurement of renal function is not practical in most clinical 
settings; therefore, clinicians often rely on estimates when making dosing decisions. 
Similarly, renal function estimates are used to assign subjects in Phase 1 pharmacokinetic 
studies, which inform dosing in late phase clinical trials and ultimately the product label. The 
Cockcroft-Gault estimate of creatinine clearance has been the standard renal function 
metric; however, this paradigm is shifting towards the Modification of Diet in Renal Diseases 
(MDRD) estimate of glomerular filtration rate (GFR). The proportion of approved new drug 
labels with dosing recommendations based on the MDRD equation was 16.7% in 2015, 
70.0% in 2016, and 46.7% in 2017. Disharmonious recommendations from the United States 
Food and Drug Administration and the European Medicines Agency will continue to increase 
this heterogeneity in the assessment of renal function in drug development and negatively 
impact industry, health systems, and clinicians. In this review, we discuss the current 
regulatory guidance for the conduct of renal impairment pharmacokinetic studies and review 
the implications of this guidance across the medication use system with three recently 
approved antibiotics: ceftazidime/avibactam, delafloxacin, and meropenem/vaborbactam. 
Finally, we suggest measuring GFR in Phase 1 studies and employing the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation to integrate data across clinical 
trials. This will help to harmonize CKD staging, population pharmacokinetic analyses, and 
dosing by estimated renal function. 
 
Keywords: regulatory science, CKD-EPI, Cockcroft-Gault, creatinine clearance, drug 
development, glomerular filtration rate, MDRD 
 
 
INTRODUCTION 
Precision pharmacotherapy relies on an understanding of the factors contributing to 
variability in drug exposure (pharmacokinetics [PK]) or drug effect (pharmacodynamics [PD]) 
within patient populations.1 While precision medicine is frequently associated with use of 
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clinical pharmacogenomics to select the right drug, dose adjustments based on genotype 
have been only minimally implemented into the regulatory process and clinical practice.2 
Because of the paucity of genomic information currently available to clinicians, dose 
individualization relies on measureable factors impacting drug PK, namely, patient body size 
and eliminating organ function.1 The kidneys are responsible for the elimination of many 
classes of xenobiotic compounds and their metabolites, making renal function the most 
common factor used to individualize drug dosing. However, methods used to measure renal 
function through the glomerular filtration rate (GFR), or surrogates thereof, are time intensive 
and impractical in most clinical settings.3 Thus, drug dosing is largely determined using 
estimates of GFR obtained from equations based on demographic variables and one or 
more renal biomarkers.3  
 The Cockcroft-Gault (C-G) estimate of creatinine clearance (eCrCL) has been the 
standard used to enroll patients with renal impairment into Phase 1 PK studies, inform 
dosing protocols in late phase clinical trials, and stratify dosing schedules in product 
labeling.4 However, since publication of draft guidance from the United States Food and 
Drug Administration (FDA) in 2010, this paradigm has been shifting towards the Modification 
of Diet in Renal Disease (MDRD) estimate of glomerular filtration rate (eGFR), despite the 
lack of a clear recommendation in favor of this equation over the C-G.5, 6 Conversely, the 
European Medicines Agency (EMA) recommends an exogenous measure of GFR be used in 
these early phase clinical trials.7 The lack of harmony between these regulatory agencies 
has created an environment of uncertainty and heterogeneity in the development of drugs 
impacted by renal function. This variability in the assessment of renal function has important 
implications for industry, regulators, health systems, and clinicians. Furthermore, the current 
trajectory towards increasing use of the MDRD equation in these settings may not be 
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optimal. In this review, we highlight the current regulatory guidance with respect to 
assessment of renal function, discuss the implications for all members of the medication use 
system, and suggest a way forward using the Chronic Kidney Disease Epidemiology 
Collaboration Equation (CKD-EPI) to harmonize drug dosing across the entire distribution of 
renal function.   
 
RENAL FUNCTION ESTIMATION IN DRUG DEVELOPMENT 
The FDA recommends renal impairment PK studies for many types of investigational 
compounds, not just those primarily eliminated unchanged in urine or those affected by the 
dialysis process.5 There is increasing recognition that hepatic and biliary drug metabolizing 
enzymes and transporters are altered in chronic kidney disease (CKD).8  Because of this, 
the FDA recommends reduced or full renal impairment studies for compounds primarily 
metabolized or secreted in bile as well as therapeutic proteins with molecular weights under 
69 kDa. Thus, most investigational drugs intended for chronic administration will be studied 
to some degree in subjects with renal impairment.5 
 The FDA suggests that subjects should be enrolled into Phase 1 renal impairment 
studies based on estimated GFR given the impracticality of measuring GFR in most clinical 
settings. This guidance recognizes the C-G equation as the historical standard for drug 
dosing in renal impairment but acknowledges that use of the MDRD is increasing in clinical 
practice. The stated position of the FDA is that “either the C-G or MDRD equation can be 
used to assign subjects to a renal impairment group or stage” but “PK results should be 
shown for both C-G estimates of creatinine clearance and eGFR”.5 Measured CrCL obtained 
via timed urine collections can be considered in individuals with abnormal variation in diet 
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(vegetarian, creatine supplements) or altered muscle mass (amputation, malnutrition, muscle 
wasting) but is not recommended routinely due to methodological challenges and high intra- 
and inter-day variability. While not included in the main text of the guidance, a table footnote 
states that measured GFR or CrCL may also be superior to prediction equations for subjects 
with acute renal failure, extremes of age or body size, and those undergoing kidney 
replacement therapy.  
 In contrast to the FDA, the EMA recommends measuring GFR using an exogenous 
compound due to improved accuracy over equation-based estimates.7 Furthermore, the 
EMA recommends reporting all GFR values, whether measured or estimated, in absolute 
units (mL/min) rather than normalized to subject BSA. The rationale for this difference is that 
renal clearance of drugs in individuals is proportional to absolute GFR rather than the BSA-
normalized values used to diagnose and stage CKD. The EMA states that presentation of 
data from Phase 1 renal PK studies should be made using an estimate of GFR, based on 
serum creatinine (Scr) or cystatin C, or an estimate of creatinine clearance. The MDRD, C-
G, and CKD-EPI equations are all listed as appropriate estimates; however, no preference is 
given to one equation over another by the EMA.7 
 The recommendations from the FDA and EMA discussed above apply only to the 
design and conduct of renal impairment PK studies in adult subjects. For pediatric subjects, 
the FDA recommends using measured CrCL or GFR determined via an exogenous indicator 
for enrollment with extrapolation to larger efficacy or population PK studies using the 
modified Schwartz equations incorporating standardized Scr and/or cystatin C.5, 9 Unlike the 
FDA, the EMA indicates that results demonstrating altered PK based on changes in GFR in 
adult patients can be extrapolated to pediatric patients in most cases.7  
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IMPLICATIONS ACROSS THE MEDICATION USE SYSTEM 
The lack of a single standard for the assessment of renal function in Phase 1 studies 
impacts all stages of the medication use system from pharmaceutical companies to 
clinicians taking care of individual patients. In this section, we discuss how the absence of a 
standardized method for quantifying renal function in early phase clinical trials leads to 
heterogeneity in study design, modeling of pooled data, regulatory review, electronic 
reporting of renal function, and ultimately drug dosing by individual clinicians. This 
heterogeneity will be highlighted throughout this section using the example of the three 
systemically available antibiotics approved by the FDA between 2015 and 2017: 
ceftazidime/avibactam (CZA), delafloxacin (DLX), and meropenem/vaborbactam (M/V).10-12 
 
Industry. When designing dedicated renal impairment studies, sponsors of investigational 
therapeutics must choose a method to enroll subjects into groups based on kidney function. 
The choice between the C-G and MDRD equations, as recommended in the 2010 FDA 
guidance, is non-trivial and may significantly impact the assignment of individual subjects to 
renal groups. The discrepancy in units between the MDRD and C-G equations, as well as 
the inherent biases of each equation, can translate to discrepancies in subject assignment 
across renal strata.  
 The FDA recommends reporting the results of the MDRD equation normalized to 
BSA (mL/min/1.73 m2) rather than in absolute units (mL/min), which results in under-
prediction of true absolute GFR in subjects with larger than average body size. Furthermore, 
the C-G equation intrinsically overestimates measured absolute GFR by approximately 15% 
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on average with even greater error in subjects with large body size.13-17 The combination of 
these biases leads to significant discordance between the two methods when assigning 
subjects to renal function groups. A review of pooled Phase 1 data from 36 new molecular 
entities approved by the FDA between 1998 and 2010 found 35.8% discordance (kappa = 
0.54, weight-kappa = 0.73) between the C-G and BSA-normalized MDRD equations.18 
Notably, this discordance decreased to 22.2% when using the MDRD equation expressed in 
absolute units (kappa = 0.71, weighted-kappa 0.87).  
 Table 1 depicts a “real-world” example of this discordance using Phase 1 data 
included in the FDA review of DLX, a fluoroquinolone antibiotic approved in 2017.11, 19 
Subjects were enrolled into four equally sized groups (n = 8) by eGFR; however, assignment 
of subjects by eCrCL demonstrated significant changes in group size and composition. Six 
subjects classified as having renal impairment by eGFR were classified as controls by 
eCrCL and only 3 of 8 subjects in the severe renal impairment category remained when 
classifying by eCrCL. These data demonstrate the inadequacy of the current approach of 
presenting PK data stratified by both eCrCL and eGFR as a method to deal with the 
discordance between these measures. 
 Clearly, the choice of GFR estimate can have a significant bearing on enrollment of 
subjects into the reference group in Phase 1 renal impairment studies. This is particularly 
relevant as the relative drug exposure between control subjects and those with renal 
impairment ultimately informs dose adjustments used in Phase 3 clinical trials. The MDRD 
study equation was developed using data from subjects screened for enrollment in a trial 
targeting participants with CKD (GFR ≤ 55 mL/min/1.73 m2). 6, 13 Due to the enrollment 
criteria for the original study,  measured GFR values in or near the normal range were 
under-represented in dataset used to develop the study equation, which results in a 
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systematic bias towards underestimation of measured GFR in the setting of normal or near-
normal kidney function (eGFR > 60 mL/min/1.73 m2). This bias persists even after correction 
for isotope dilution mass spectrometry (IDMS) traceable serum creatinine values.6, 14 
Correspondingly, the National Kidney Disease Education Program (NKDEP) recommends to 
avoid reporting actual eGFR values above 60 mL/min/1.73 m2 determined using the MDRD 
equation underscoring the limitations this equation to enroll subjects with normal renal 
function into Phase 1 studies.20  
 Figure 1 highlights the different strategies used to enroll subjects across the clinical 
programs of CZA, DLX, and M/V. Subjects were enrolled into the dedicated renal impairment 
PK studies using the C-G equation for CZA, the MDRD equation for DLX, and a hybrid 
approach for M/V.19, 21, 22 The hybrid approach used in the Phase 1 study of M/V enrolled 
subjects into the healthy control group using the C-G equation (eCrCL > 90 mL/min) and the 
renal impairment groups via the MDRD equation (eGFR < 90 mL/min/1.73 m2) to account for 
the limitations of the MDRD equation at near-normal values of eGFR.22 Interestingly, despite 
the fact that the dedicated renal PK studies of both DLX and M/V used the MDRD equation 
to define renal impairment, exclusions and dose adjustments for renal dysfunction in their 
Phase 2 and 3 trials were based on eCrCL rather than eGFR (Figure 1).23-26  
 
Pharmacometricians. Given the relatively small number of subjects with renal impairment 
enrolled across all phases of clinical drug development, analysis of pooled data is necessary 
to evaluate the effect of renal impairment on drug exposure across the population. 
Pharmacometricians use population modeling and simulation to perform structured 
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evaluation of covariate effects on drug PK. The resulting models are subsequently used for 
simulations to identify optimal dosing regimens designed to maximize the drug PD profile.  
 Defining an accurate covariate structure in the population PK model is reliant on the 
distribution of each covariate in the underlying population. Therefore, a measure or estimate 
of renal function which is valid and unbiased across the entire distribution of GFR is 
necessary to accurately assess the impact of renal function on drug PK using a population 
approach. The traditional renal dosing paradigm has been unidirectional and focused 
exclusively on renal impairment. It is increasingly recognized that a bidirectional strategy, 
employing adjustments for both renal impairment and augmentation, may be necessary. This 
is exemplified by the direct acting oral anticoagulant edoxaban, which carries a black box 
warning for reduced efficacy in patients with eCrCL > 95 mL/min, possibly due to under 
dosing in patients with good renal function.27  
 Glomerular filtration rate measured directly using an exogenous substance provides 
the most unbiased and accurate measure of renal function across the entire distribution; 
however, it is methodologically cumbersome and costly to implement in late phase clinical 
trials. Therefore, even if exogenously measured GFR becomes the standard for Phase 1 
studies, as suggested by the EMA, it is unlikely to ever be useful for modeling of pooled data 
from all phases of clinical development. The C-G equation is valid across the entire 
distribution of renal function; however, it suffers from significant bias. The MDRD equation 
provides a more accurate and unbiased measure of GFR in renal impairment but 
systematically under-estimates GFR in subjects with normal or near-normal renal function.  
 Multiple challenges exist for pharmacometricians in modeling the PK of drugs 
eliminated by the kidneys. The use of renal function estimates that suffer from systematic 
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biases (e.g. >60 mL/min/1.73m2 for MDRD) limits the utility of estimated renal function as a 
covariate in population PK model development. This limitation is also compounded by the 
inability of current serum creatinine-based estimates to account for intra-patient variability in 
PK due to the time-varying, dynamic nature of GFR and disease pathophysiology. Renal 
function estimates based on single serum creatinine measurements require those values to 
be obtained at steady-state. The estimation of GFR in clinical conditions such as sepsis and 
acute kidney injury is at present unreliable. This limitation of the common serum creatinine 
based renal function estimates impacts dose selection of drugs used to treat acute illnesses, 
such as the broad-spectrum antibiotics discussed here. Select drugs that are eliminated 
unchanged in urine can also cause acute kidney injury which adds an additional layer of 
complexity to population PK model development due to a potential reduction in clearance 
over time due to nephrotoxicity. Modeling and simulation of drugs to define dosing can also 
be impacted by the excipients used to solubilize them. For example, the intravenous 
formulation of DLX contains the excipient, sulfobutyl-ether-β-cyclodextrin (SBECD), which is 
primarily eliminated unchanged in urine.11, 28 Studies in animal models suggest the risk for 
liver and renal injury increases when high concentrations of SBECD are present.28 This risk 
has supported dose labeling recommendations for some drugs, such as intravenous 
voriconazole, even though the clearance of the active pharmaceutical ingredient is not 
dependent on GFR.29 The effects of drugs or drug excipients on subject renal function, 
unlike the effects of renal function on drug PK, are often difficult to quantify in short-term 
clinical trials but, nonetheless, represent an important safety consideration in drug 
development. 
 Figure 1 highlights the different approaches taken by industry pharmacometricians to 
evaluate the effect of renal function on the PK of CZA, DLX, and M/V. The population PK 
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model of CZA used eCrCL to model renal function, which is consistent with the use of this 
equation throughout its clinical program.10 The population PK model of DLX was developed 
using a modified C-G equation calculated using the lesser of ideal and actual body weight 
and normalized to BSA.11 This modified C-G equation was not used for subject enrollment or 
stratification in any clinical trials of DLX. The M/V population models were constructed using 
the MDRD equation to model all levels of eGFR despite the known limitations of this 
estimate in subjects with normal or near normal renal function.12  
 
Regulators. The use of both the C-G and MDRD equations in drug development increases 
the burden placed upon regulators when reviewing new drug applications (NDAs). The 
clinical pharmacology and biopharmaceutics review relies heavily on the assessment of 
pooled PK data from healthy subjects and patients both with and without renal impairment. 
Simulations using the population PK model are an integral method used to explore 
exposure-efficacy and exposure-toxicity relationships in special populations under-
represented in clinical trials, including those with renal impairment. Because both the C-G 
and MDRD equations may be used in different clinical trial phases for the same 
investigational drug, regulators are frequently forced to consider the impact of different 
estimates of renal function on models and simulations.  
 In the review of DLX, the FDA assessed the relationship between various 
permutations of the C-G and MDRD equations using pooled Phase 3 data.11 This analysis 
demonstrated a high correlation between the modified C-G equation used by the sponsor 
and MDRD equation (r = 0.92), but poor correlation between the modified and standard C-G 
estimates (r = 0.61). Because of the sponsor’s modified C-G equation appeared to correlate 
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better with the MDRD equation than the standard C-G, the FDA reviewer re-analyzed the 
population PK data using the MDRD equation, which was eventually incorporated into the 
final product label.11  
 The FDA review of M/V highlights a different challenge to regulators due to variable 
methods of assessing renal function. The sponsor proposed a different renal dosing scheme 
for the product label than that used in the Phase 3 trial based on a probability of target 
attainment analysis performed using simulations derived from the population PK model.12 
These simulations were based on the assumption of a uniform distribution of eCrCL and 
bootstrapped covariate values obtained from the Phase 3 population. For the simulations, 
eCrCL was normalized to BSA and input as eGFR into the population model. Therefore, 
although the population model was built using the MDRD equation, the simulations which 
informed the final labeled dosing were performed using the C-G equation normalized to 
BSA. However, among subjects enrolled in the Phase 3 program of DLX, the correlation 
between the BSA-normalized C-G and MDRD estimates was 0.86.11 Although normalizing 
eCrCL to BSA produces units equivalent to eGFR, these estimates of renal function are not 
interchangeable. 
 
Clinicians and Health Systems. The complexity underlying the current practice of 
assessing renal function in clinical trials is not communicated to clinicians and health 
systems. These “end users” of drug dosing information receive only the final 
recommendations contained within the product label. This information must then be 
integrated into renal dose adjustment policies and protocols within the health system, which 
are intended to apply universally to all drugs requiring renal adjustment. The majority of 
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electronic health systems present renal function as eGFR calculated using the MDRD 
equation, which likely reflects the utility of the MDRD equation in staging CKD more than its 
applications to drug dosing.30  
 Integration of newly-approved drugs into existing renal dosage adjustment protocols 
may necessitate more complicated branching logic in electronic health systems or increased 
clinician awareness of the equations underlying labeled dose adjustments for individual 
drugs. Additionally, because the C-G equation is not recommended for staging CKD, an 
estimate of eGFR will need to be relayed to clinicians regardless of its utility in drug dosing. 
The most useful output for the electronic health system would be a value that is both useful 
for staging CKD and quantifying the entire distribution of patient renal function. However, 
given that the majority of renal dose adjustments of currently available drugs are based on 
the C-G equation, transition to any new estimate of renal function will need to be applicable 
to existing drugs on the market.     
 
THE FORK IN THE ROAD 
 “When you come to a fork in the road, take it”- Yogi Berra 
The current paradigm for assessing renal function in drug development introduces 
unnecessary heterogeneity in approaches to drug dosing in renal impairment. This is a 
complex problem and a true solution is unlikely as long as Scr remains the primary renal 
biomarker used in clinical practice. These inadequacies of Scr are well documented and 
include high inter-individual variation in production (diet, muscle mass) and elimination 
(tubular secretion) across the population.31 Although, alternate biomarkers perform better 
than Scr in some settings, such as early detection of acute kidney injury, their overall clinical 
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utility, standardization, and reimbursement remain to be defined.32 This multi-role application 
of Scr as a marker of renal function, renal injury, and drug dosing forces retention of this 
biomarker as the standard for classifying CKD and determining drug dosing in the near 
future.  
 The C-G and MDRD equations recommended by the FDA have multiple limitations 
impacting all users within the drug development and medication use systems. The C-G 
equation was determined by linear regression of only 7 data points representing mean 
measured creatinine excretion for male veterans averaged over decade intervals of age.4 
The use of measured CrCL as the reference method for this equation leads to over-
prediction of true GFR due to tubular secretory clearance of creatinine and the bias inherent 
to development prior to creatinine standardization in clinical laboratories.14 Indeed, the use of 
IDMS-traceable serum creatinine values in clinical laboratories today increases the 
inaccuracy of C-G eCrCL as this equation cannot be re-expressed for standardized serum 
creatinine values.14 The MDRD equation, re-expressed for standardized creatinine values, 
demonstrates reduced bias relative to the C-G equation in subjects with renal impairment but 
is limited by systematic under-prediction of true GFR in subjects with normal or near-normal 
renal function.6, 14 Additionally, the use of BSA-normalized eGFR values for subjects with 
non-standard body size leads to error in the prediction of the true absolute GFR underlying 
drug elimination.  
 We reviewed labels for new drugs approved by the FDA between 2015 and 2017 in 
order to assess the equations used to inform dosing recommendations in patients with renal 
impairment. New drug approvals for each year were obtained from the FDA website 
(https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/). Approved 
product labeling was reviewed for each of the approved drugs, and supporting regulatory 
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review documents available within the public domain were referenced in cases where the 
equation underlying dosing recommendations in renal impairment was not explicitly stated. 
Dosing recommendations comprised both labeled dose reductions for renal impairment as 
well as labeled information confirming that no dose adjustment was required in renal 
dysfunction, as defined by a specified estimate of renal function. Drugs without dosing 
recommendations based on estimated renal function were excluded; therefore, the 
denominator for each year consists of all drugs approved during that year with dosing 
recommendations based on renal function.  
 In 2015, 24 of 29 (82.8%) approved drug labels included assessment of patients with 
renal impairment based on the C-G equation. In 2016, 7 of 10 (70.0%) labels were based on 
the MDRD equation, and in 2017 similar proportions of newly approved drug labels 
referenced the C-G (8/15, 53.3%) and MDRD (7/15, 46.7%) equations, respectively. 
Regardless of magnitude, there is a trend towards increasing use of the MDRD equation 
relative to C-G for drug dosing. This shift is resulting in discordant equation use for drugs 
within classes, as highlighted by delafloxacin (fluoroquinolones) and 
meropenem/vaborbactam (carbapenems). It is clear that the extended time horizon from 
design of Phase 1 studies to FDA approval creates a significant delay between 
implementation of guidance to industry and impact on approved drugs. Therefore, it is even 
more urgent that regulators address the existing limitations of current guidance and adapt 
quickly to improvements in the state of the art of renal function assessment.  
 Given the imprecision of all serum creatinine-based models for the estimation of 
renal function, it seems prudent to enroll and stratify the small number of subjects included in 
dedicated Phase 1 renal impairment studies using an exogenous measure of GFR. This is in 
line with the current recommendations from the EMA as well as a policy statement from 
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experts convened by Kidney Disease: Improving Global Outcomes (KDIGO).7, 33 While 
measuring GFR using exogenous markers is impractical in later phase clinical trials, it can 
be performed in the relatively small sample of heathy subjects studied during Phase 1. This 
practice will ensure that the limited dedicated PK data from patients with renal impairment 
will be based on a “gold standard” reference value and reduce the risk for misclassification.  
 Estimates of GFR are required to screen patients for enrollment in Phase 2 and 3 
trials and to inform pooled analyses of PK data from the entire clinical program. In our 
opinion, the CKD-EPI equation addresses many of the limitations of its predecessors and 
represents an opportunity to standardize renal function assessment across drug 
development.34 First, the CKD-EPI equation was validated on pooled data from studies with 
exogenous measures of GFR representing the entire distribution of renal function.34 
Therefore, the CKD-EPI equation retains the advantage in precision of the MDRD equation 
without the systematic bias at normal or near-normal values of eGFR making it a useful 
measure for enrollment and pooled data analysis. Second, the CKD-EPI equation can be 
used both to stage CKD and determine drug dosing, which makes it a more optimal measure 
for implementation in clinical laboratory reporting and electronic health systems. However, 
because drug elimination is often related to absolute, rather than BSA normalized, 
glomerular filtration rate; eGFR values may need to be de-normalized for drug dosing as 
recommended by the EMA.7 A comparison of the three primary serum creatinine-based 
models for estimating renal function is presented in Table 2. 
 The CKD-EPI equation has demonstrated utility in predicting drug pharmacokinetics 
and informing dosing. Studies with the aminoglycosides, compounds that serve as excellent 
probes of glomerular filtration, have verified that the CKD-EPI equation is likely to be more 
precise than either the C-G and MDRD equations.35, 36 The CKD-EPI equation has also 
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shown to be relevant for stratification of risk when dosing edoxoban in patients with good 
renal function.37 Also, the CKD-EPI estimates of renal function led to concordant dosing 
recommendations of antiretroviral dosing in a French cohort of patients with HIV.38 Notably, 
these studies have demonstrated that concordance is best using absolute (mL/min) rather 
than BSA normalized (mL/min/1.73m2) estimates of renal function.  
 The CKD-EPI equation represents an incremental improvement in the assessment of 
renal function rather than a fundamental paradigm shift. All the limitations of Scr as a 
biomarker still apply to the CKD-EPI equation although newer versions of this equation 
incorporating cystatin C, with or without Scr, have also been developed.39 Additionally, the 
effect of race in the CKD-EPI equation has been found to vary across racial and ethnic 
groups distinct from those used to train the original model.40-42 The current race factor 
appears to be appropriate in Black Americans or people of European descent; however, it 
may not be valid in black African or Asian populations.40-42 Re-expression of the CKD-EPI 
equation using the ratio of measured serum creatinine to a race- and sex-based population 
median value may improve use of this equation in settings outside of the United States and 
Europe.43 Although more research is needed to validate this approach, it should be 
recognized that this variable can be accounted for in bridging studies dedicated to dose 
optimization across race and ethnicity.  
 
CONCLUSION 
The current regulatory guidance for the assessment of renal function in drug development is 
increasing heterogeneity in study design and data analysis for investigational therapeutics. 
Both the C-G and MDRD equations are used across drug development without a 
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predominant approach advocated by regulatory agencies. The CKD-EPI equation provides 
an incremental improvement over both the C-G and MDRD equations and offers a method to 
standardize the assessment of renal function in clinical trials, pooled data analysis, and 
clinical practice. Given the significant time horizon between early phase PK studies and 
regulatory approval of novel therapeutics, regulatory agencies should update current 
guidance to industry in line with the evolving state of the art in the assessment of patient 
renal function. Incorporation of measured GFR in Phase I studies with later assessment via 
the CKD-EPI equation is a necessary consideration for regulators to avert the expected 
discordance with use of the C-G and MDRD equations. 
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Figure 1: Assessment of renal function throughout the drug development process for the 
three systemically active antibiotics approved by the FDA since 2015. Abbreviations: C-G, 
Cockcroft-Gault equation; C-GIBW,BSA, Cockcroft-Gault equation calculated using the lesser of 
ideal and actual body weight and normalized to body surface area; MDRD, Modification of 
Diet in Renal Disease equation; PK, pharmacokinetic 
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Table 1: Discordant Classification of Subjects Enrolled in a Phase I Study of Delafloxacin 
using the Cockcroft-Gault and Modification of Diet in Renal Disease Equations 
  MDRD Cockcroft-Gault 
Group 
eGFR 
or 
eCrCLa 
N 
Geometric LS 
Mean AUC0-t
b
  
AUC Ratio 
(90% CI) 
N 
Geometric LS 
Mean AUC0-t
b 
AUC Ratio 
(90% CI) 
Healthy 
subjects 
> 80  8 23.12 Reference 14 25.55 Reference 
Mild 
Impairment 51-80  8 30.51 
1.32 
(0.93, 1.87) 
7 34.97 
1.37 
(0.99, 1.89) 
Moderate 
Impairment 31-50  8 38.20 
1.65 
(1.17, 2.35) 
8 48.39 
1.89 
(1.39, 2.58) 
Severe 
Impairment ≤ 30  8 46.57 
2.01 
(1.42, 2.86) 
3 39.87 
1.56 
(1.00, 2.43) 
Abbreviations: MDRD, Modification of Diet in Renal Disease equation; eGFR, estimated 
glomerular filtration rate calculated using the MDRD Equation; eCrCL, creatinine clearance 
calculated using the Cockcroft-Gault equation; AUCo-t, area under the concentration time 
curve [AUC] from time 0 to the last quantifiable concentration; CI, confidence interval 
aeGFR was measured in units of mL/min/1.73 m2 while eCrCL was measured in units of 
mL/min 
bAUC values were obtained following a single intravenous dose of 300 mg and are 
presented in units of µg*h/mL 
Data from references 11 and 19 
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Table 2: Comparison of the Three Primary Serum Creatinine-based Equations Used to 
Estimate Renal Function 
 
Cockcroft-Gault MDRD CKD-EPI 
Study Characteristics 
Year  1976 
1999 (6 variable) 
2006 (4 variable) 
2009 
Reference Method 
24-hour creatinine 
clearance 
125I-iothalamate 
clearance 
125I-iothalamate 
clearance 
Enrollment (Males / Females) 249 / 0 983 / 645  3113 / 2391  
Patient Renal Functiona 
73 ± 37  
mL/min 
40 ± 21 
mL/min/1.73 m2 
68 ± 40  
mL/min/1.73 m2 
Comparison of Equations 
Variables 
age, sex, serum 
creatinine, weight 
age, sex, serum 
creatinine, race 
age, sex, serum 
creatinine, race 
Developed using an 
exogenous measure of 
GFR? 
NO YES YES 
Developed or re-expressed 
for use with IDMS-traceable 
serum creatinine? 
NO YES YES 
Valid across the full spectrum 
of renal function? 
YES NO YES 
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Currently recommended for 
staging of CKD? 
NO YES YES 
Currently recommended for 
drug dosing by regulatory 
agencies? 
YES YES 
FDA: NO 
EMA: YES 
Abbreviations: MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; CKD, chronic kidney disease; IDMS, isotope dilution 
mass spectrometry; GFR, glomerular filtration rate; FDA, United States Food and Drug 
Administration; EMA, European Medicines Agency 
a Data presented as mean ± standard deviation 
 
 
 
